Article Text

PDF

Introducing high-flow nasal cannula oxygen therapy at the intermediate care unit: expanding the range of supportive pulmonary care
  1. Joost D J Plate1,
  2. Luke P H Leenen1,
  3. Marc Platenkamp2,
  4. Joost Meijer3,
  5. Falco Hietbrink1
  1. 1Division of Surgery, Universitair Medisch Centrum Utrecht, Utrecht University, Utrecht, The Netherlands
  2. 2Department of Intensive Care Medicine, University Medical Centre Utrecht, Utrecht University, Utrecht, The Netherlands
  3. 3Department of of Intensive Care Medicine, Noordwest Ziekenhuisgroep, Utrecht, The Netherlands
  1. Correspondence to Joost D J Plate, Division of Surgery, Universitair Medisch Centrum Utrecht, Utrecht, 3584CX, The Netherlands; j.d.j.plate{at}umcutrecht.nl

Abstract

Background Non-invasive respiratory support is a frequent indication for intermediate care unit (IMCU) admission. Extending the possibilities of respiratory support at the IMCU with high-flow nasal cannula oxygen therapy (HFNC) may prevent intensive care unit (ICU) transfer and invasive ventilation. However, the safety and limitations of HFNC administration in the stand-alone IMCU setting are not yet studied. This study therefore aims to investigate to what extent and in which patients HFNC can safely be administered at a stand-alone mixed surgical IMCU.

Methods A case series, using retrospectively collected data, was performed after the first year of introducing HFNC at a stand-alone IMCU. The following variables were collected: indication to start HFNC, vital parameters and arterial blood gas measurements. Primary outcome was 30-day mortality. Secondary outcome was transfer to the ICU.

Results A total of 96 admissions were included. The indications to start HFNC at the IMCU were predominantly pathologies of pulmonary origin (n=67, 69.8%). Less frequent indications were prolonged support postweaning (n=15), non-pulmonary sepsis (n=7) and post-trauma resuscitation (n=6). The average PaO2/FiO2ratio at start of HFNC was 152 (95% CI 139 to 165). 30-day mortality was 7, of which 5 were admitted with treatment restrictions (no ICU policy) and 2 deaths were unrelated to HFNC. Transfer to the ICU occurred in 18 (18.8%) admissions, of which 12 received invasive mechanical ventilation. Reason for ICU transfer was mainly PaO2/FiO2 ratio<100 under maximum non-invasive treatment (n=12, 66.7%). Application of HFNC at the IMCU prevented 162 days of ICU admission.

Discussion Administration of HFNC at a stand-alone surgical IMCU may be safe as it expands the range of supportive possibilities and thereby reduces the need for ICU admissions.Pulmonary indications to start HFNC increase the risk of ICU transfer and mechanical ventilation.

Level of evidence Level VI.

  • acute care
  • acute care surgery
  • critical care
  • trauma/ critical care

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

Statistics from Altmetric.com

Introduction

Non-invasive respiratory support is a common reason to admit patients to the intermediate care unit (IMCU). Through extending the possibilities of the respiratory capabilities at the IMCU, intensive care unit (ICU) admission and mechanical ventilation may be prevented.

Mechanical ventilation is almost always a limitation of IMCUs, but an increase in the range of other supportive respiratory care at IMCUs can reduce the need to transfer patients from the IMCU to the ICU.1 In an IMCU in which the admitting specialist remains in charge (a so-called ‘open’ format), this reduces handovers to the intensivist. In this case, the admitting specialist continues to provide specialized care.2 Whether extended possibilities can safely be applied at a (stand-alone) IMCU and for which patients, however, is not yet studied.

All IMCUs provide standard respiratory support, which includes the administration of oxygen via nasal cannula, nasal tube or (non-rebreathing) oxygen mask.1 Extended respiratory support, which entails high-flow nasal cannula oxygen therapy (HFNC), non-invasive mechanical ventilation (NIV) and invasive mechanical ventilation, however, is less common. Especially the administration of HFNC at IMCUs is uncommon, as this was only reported as a possibility at one IMCU.1 3

HFNC is an oxygen administration method which allows for delivering warmed and humidified gas (air and oxygen) at very high flow rates via a nasal cannula. This improves the oxygenation, decreases respiratory work and improves patients' well-being and is a useful option in patients with acute hypoxic respiratory failure.4 In addition, it has shown to significantly decrease mortality and intubation rates compared with standard oxygen therapy, potentially making this technique a suitable replacement for standard respiratory support.5 6 Also, HFNC can be used for acute respiratory failure when the standard methods of respiratory support are insufficient and NIV or intubation are not (yet) indicated.7 However, hypercapnic respiratory failure is a limitation of HFNC administration.

HFNC was recently implemented in our stand-alone mixed surgical IMCU. The aim was to assess the safety of HFNC provided at the IMCU.

Methods

Study design and setting

A case series, using retrospectively collected data, was conducted at the surgical IMCU of the University Medical Centre in Utrecht, a tertiary university referral hospital in the Netherlands. This independent, surgical IMCU admits patients from all surgical disciplines, providing hemodynamic monitoring and cardiovascular and respiratory support including inotropic use and supplementary oxygen. It has an open format with 24/7 supervision of surgeons with additional critical care certifications for hemodynamic and respiratory support. Its limitations are non-invasive and invasive mechanical ventilation, continuous renal replacement therapy and—until recently—HFNC. A general mixed-specialty closed format ICU run by intensivists is available for consultation and take over if necessary. In case of maximum HFNC support, intubation at the IMCU is required before patient transfer since transport with HFNC is logistically not possible in our setting.

In July 2016, HFNC was implemented at the IMCU to provide the possibility for extended respiratory support in patients with non-hypercapnic hypoxemic respiratory failure. The medical criterion to start HFNC was inadequate oxygenation under supportive respiratory care with an oxygen mask at 40%–100% oxygen, 10–15 L/min. To wean from HFNC, the protocol was to first lower the FiO2 and then the oxygen flow. Subsequently, at HFNC settings of 30% FiO2 with 30 L/min, a switch to the (non-rebreathing) oxygen mask was considered. These settings were lowered after assessment of the arterial blood gas and pulse oximetry measurements at the discretion of the physician (in collaboration with the nurses). A respiratory therapist was not involved in this weaning process.

After training of the nurses and doctors with the equipment, the first patient received HFNC at 15 July 2016. From that date until 16 August 2017, all patients which received HFNC during IMCU admission were included in this study.

According to the Institutional Review Board, the study was not subject to the Medical Research Involving Human Subjects Act and therefore the necessity of informed consent was waived.

Study variables: baseline

The following baseline variables were collected: age, sex, admission location, underlying diagnosis of hospital admission, the admission duration at the IMCU, cardiovascular and pulmonary comorbidities, the Sequential Organ Failure Assessment (SOFA) score8 and the American Society of Anesthesiologists (ASA) classification.9 If an item of the SOFA score was not measured within 3 days before admission at the IMCU, this item was considered normal. This approach assumes that there was—apparently—no clinical reason to measure this and thus abnormalities are unlikely.

Study variables: indication HFNC and vital signs

To explore the indication of HFNC and the actual patient condition at the start of HFNC, the following variables were collected: indication to start (categorized in four categories: pathologies of pulmonary origin, postweaning of mechanical ventilation (ICU or postanesthesia care unit), sepsis (due to non-pulmonary causes) and post-trauma resuscitation), vital parameters (heart rate, mean arterial pressure, respiratory rate, saturation), laboratory investigations (CRP and leukocyte count) and an arterial blood gas within 6 hours of start of the HFNC, including a calculation of the P/F ratio (PaO2 of oxygen (PaO2)/fraction of inspired oxygen (FiO2) ratio).

The administered FiO2 of patients that received oxygen via nasal cannula or tube before receiving HFNC, was calculated according to previous measurements concerning intratracheal FiO2 for 2 and 4 L of oxygen per minute.10 The FiO2 values for 3, 5 and 6 L of oxygen administration per minute were, respectively, intrapolated and extrapolated using their provided formula. This has led to an approximated FiO2 of 29.6% in 2 L/min, 32.75% for 3 L/min, 35.9% for 4 L/min, 39.7% for 5 L/min and 43.5% for 6 L/min. These values were based on a respiratory rate of 15 per minute, in healthy subjects. However, it is known that the FiO2 alveolar value drops in ill patients. In addition, low flow oxygen by cannula depends on breathing pattern.11 To determine the P/F ratio at the time of ICU transfer (if applicable), the set FiO2 at the HFNC was used.

Study variables: utilization of HFNC

The utilization of HFNC was analyzed using the following variables: flow (in L/min) and FiO2 (in percentage) at start, duration of the HFNC at the IMCU, maximal flow (in L/min) and maximal FiO2 (in percentage) during HFNC support. Whether the ICU was consulted at the start or during HFNC administration was also reported.

Study outcome: mortality and ICU transfer

To assess the safety of HFNC at the IMCU, the 30-day mortality after the start of HFNC was used as the primary outcome and transfer to the ICU rate as secondary outcome. In our hospital, HFNC was also occasionally used as maximal conservative treatment in the (elderly) patient without chances of recovery and non-ICU transfer policy. The overall 30-day mortality was subdivided into deaths with and without restrictions to maximal treatment.

The secondary outcome parameter, ICU transfer rate, was complemented with both the arterial blood gas at transfer and the reason for ICU transfer (intubation, NIV or other reasons). Transfers from the IMCU via the operating room to the ICU were not seen as a negative (or undesired) outcome, since these patients had an underlying problem which needed surgical therapy and thus were not transferred to the ICU for increased respiratory support. Hence, HFNC administration at the IMCU was classified as successful as the patient was subsequently transferred to the hospital ward or operating room and unsuccessful if a patient was transferred to the ICU.

Statistical analyses

Continuous variables were described with the mean and the 95% bias-corrected and accelerated CIs, to also describe the skewness of the data. To analyze the associations between variables, the following univariable analyses were performed: Kruskal-Wallis tests (continuous outcomes) and the Fisher’s exact test (categorical variables). In comparing the successful versus unsuccessful administrations of HFNC, deaths at the IMCU were excluded since these patients were admitted for another reason (maximum supportive care) and hence, appropriateness of HFNC admissions could not be determined. A multivariable logistic regression analysis to identify predictors for ICU transfer was not performed due to too few events.

Throughout the analyses, a level of significance of 0.05 was used. All statistical analyses were performed using R software for statistical computing V.3.3.2,12 with the additional package ‘bootstrap’.13

Results

An overview of the baseline characteristics of admissions at the IMCU during the study period is provided in table 1. A total of 96 admissions were included.

Table 1

Baseline characteristics of admissions for high-flow nasal cannula oxygen therapy

Indications to start HFNC

The indications for HFNC were predominantly due to pulmonary pathologies (n=68, 70.8%) (table 2). Postweaning (n=15), non-pulmonary sepsis (n=7) and post-trauma resuscitation (n=6) were less frequent indications to start HFNC at the IMCU. Of the patients with atelectasis, four also had pleural effusions due to side effects from fasciitis, pancreatitis or vascular disease. The pleural effusion in the fasciitis and abdominal aortic aneurism patients were presumed reactive and therefore drained, after which the respiratory status improved and patients were weaned from HFNC within a couple of hours. In the vascular patients, the pleural effusion was supposed to reflect a (partial) fluid overload in patients with decreased cardiac function. No draining was performed in these patients.

Table 2

Indications to start high-flow nasal cannula oxygen therapy

Vital signs at the start of HFNC

Table 3 shows the vital signs at the start of HFNC at the IMCU. There were no significant differences in vital signs per indication.

Table 3

Vital signs at the start of high-flow nasal cannula oxygen therapy

Utilization of HFNC at the IMCU

On average, the starting values of the HFNC at the IMCU were 38 L/min flow (95% CI 36 to 40) and 59% FiO2 (95% CI 57.0 to 61.5). The average duration of administered HFNC was 40.4 hours (95% CI 33.5 to 49.3). Maximum settings used during IMCU admission were on average 42 (95% CI 40 to 43) L/min and 68% (95% CI 65 to 71) FiO2. There were no (significant) differences in utilization per indication or underlying diagnoses. In total, HFNC was administered for 3878 hours (162 days) during the study period. The intensivist was consulted in 41 (42.7%) admissions.

Mortality

The 30-day mortality was seven (table 4). Of these deaths, five were admitted at the IMCU with treatment restrictions (policy at admission was to not admit at the ICU anymore, due to metastases (n=2) or bad general condition (n=3)). Of the two deaths without treatment restrictions, one died at the hospital ward 5 days after the end of HFNC treatment at the IMCU; this patient died of an intra-abdominal bleeding with unknown cause. The other was discharged home in good medical condition, although with the wish for euthanasia. The eventual cause of death was unknown.

Table 4

Outcome of high-flow nasal cannula therapy at the intermediate care unit

Transfer to the ICU

A total of 18 (18.8%) admissions were transferred to the ICU. The reason for ICU transfer was a low P/F ratio (mean 75.3 (95% CI 67.19 to 83.15), all below 100) in 12 admissions, hypercapnia in 3 admissions, shock in 1, intolerance for HFNC in 1, renal replacement therapy in 1 and clinical manifestations of respiratory muscle failure in 1 admission. Mean time from start HFNC to ICU transfer was 38.32 hours (95% CI 26.05 to 54.89).

Of these 18 ICU transfers, 12 (66.7%) received invasive mechanical ventilation, 5 received non-invasive mechanical ventilation and 1 was transferred for renal replacement therapy while continuing HFNC. The 30-day mortality of ICU transfers was 0.

In total, of the IMCU population that received HFNC, 12.5% required invasive mechanical ventilation. Of the patients which were transferred to the ICU for invasive mechanical ventilation, 12 (70.6%) were immediately transferred after initial intensivist consultation, while 5 were transferred after potential delay between ICU consultation and transfer.

The studied variables at admission, distinguished by those in who HFNC was successfully (transferred to ward or operating room) or unsuccessfully (transferred to ICU) administered are shown in table 5. Of all the unsuccessful cases, 10 (55.6%) were initially admitted from the hospital ward, 4 from the emergency room, 3 from the ICU and 1 from the postanesthesia care unit.

Table 5

Successful administration of high-flow oxygen therapy at the intermediate care unit.

Unsuccessful admissions were nearly always (n=16, 88.9%) admissions which received HFNC for pulmonary indications. Per pulmonary indication to start HFNC, five admissions (38.6%) with atelectasis and pleural fluid, six admissions with pneumonia and three with a combined pulmonary problem were transferred to the ICU. This did not occur in postweaning or sepsis (due to non-pulmonary indications) admissions. Of the post-trauma resuscitation admissions, three admissions (all with pulmonary contusion) were transferred to the ICU.

Discussion

This study is the first to report to what extent and for which patients HFNC can safely be applied at the IMCU. The observed 30-day mortality was seven (7.3%). However, these included five admissions with treatment restrictions at admission, while the other deaths were not related to the HFNC treatment. Transfers to the ICU (18.8%) occurred mainly in case HFNC was initiated for pulmonary indications or for post-traumatic pulmonary contusion. Patients with atelectasis with pleural fluid, pulmonary contusion or pneumonia are at highest risk for ICU transfer. Transferred patients (94.5%) received (non)-invasive mechanical ventilation at the ICU, most commonly due to low P/F ratio (<100) under maximum HFNC settings.

These findings indicate that the range of supportive respiratory care at IMCUs may safely be expanded with HFNC, provided there is sufficient knowledge and adequate triage. Since these patients were otherwise cared for on the ICU, this could save—costly—ICU capacity for the more severe patients (in the present study >160 ICU days). However, the possibility of HFNC at the IMCU could also have decreased the threshold for its administration. Although this perhaps means that not every HFNC patient at the IMCU would have been admitted at the ICU, it may still be preferable to the oxygen mask, as this is reported to significantly decrease the in-hospital mortality and need of mechanical ventilation as compared with conventional oxygen therapy.5 6 On the other hand, the low mean observed P/F ratio of 152 (95% CI 139.8 to 166.0) indicates that most patients are at the more severe end of the spectrum of lung function limitation before the start of HFNC,14 contradicting a decreased threshold for the start of HFNC.

This study also provides a few tools for the physician to recognize those patients at risk for ICU transfer and mechanical ventilation, namely those patients with atelectasis with pleural fluid and pneumonia. For those patients, timely consultation of an intensivist should be considered. However, to truly adequately recognize patients at risk for ICU transfer, future research should focus on multivariable prediction of this outcome.

Earlier observational research toward the safety of administration of HFNC has been performed at the ICU. One study (n=38) showed that—in patients with a mean PF ratio of 102 (SD of 23)—the ICU mortality was 7.9% with an invasive mechanical ventilation rate of 23.7%.15 In another, randomised controlled trial (n=106) in HFNC patients with an PaO2/FiO2 of 157 (SD of 89), the ICU mortality was 11% and 90-day mortality was 12%. The observed invasive mechanical ventilation rate was 38%.5 This present study is in line with these previous ICU reports in the context of a similar 30-day mortality. Although—as discussed before—our IMCU included patients with restrictions to treatment (especially restrictions in ICU admission). On the other hand, our case-mix was likely different from that of the ICU in that the IMCU admitted mainly single organ failure patients, as indicated by the relatively low SOFA score of 3.7 (95% CI 3.3 to 4.1). This underlines the importance of adequate triage.

Furthermore, since deteriorating HFNC patients frequently require mechanical ventilation, it is a necessity to have (rapid) backup from an adequately functioning ICU. Especially since HFNC in a stand-alone IMCU potentially delays ICU transfer, with subsequent acute need for mechanical ventilation and delay in deposition.

This study did not assess the safety of HFNC administration by comparing its use at the IMCU versus the ICU setting. However, we believe that the absence of any HFNC-related (30-day) mortality in these 96 patients indicates that administration of HFNC in this setting may be safe for non-hypercapnic hypoxia patients.

Since our low numbers of events hampered a valid—multivariable—identification of HFNC patients at risk for ICU transfer (and mechanical ventilation), this should also be the focus of further research. With the added knowledge that IMCU may be a safe setting to administer HFNC, an important first step can be taken in the process of acquiring this knowledge. Furthermore, in-depth analysis for specific subgroups of patients (eg, thoracic trauma or acute pancreatitis) was not possible due to the heterogeneous population of included patients, which reflects common practice at our IMCU.

Conclusions

The application of HFNC at a stand-alone surgical mixed IMCU may be safe and expands the range of respiratory support possibilities, reducing the need for ICU admissions. Pulmonary indications to start HFNC (especially atelectasis with pleural fluid and pneumonia) increase the risk of ICU transfer and mechanical ventilation. Further research is needed to identify risk factors for this ICU transfer.

References

View Abstract

Footnotes

  • Contributors JDJP made substantial contributions to design, data collection, data analysis and the interpretation. He was the main author involved in drafting and finalizing the manuscript. LPHL was involved in the design and critically revised the manuscript. He has given final approval of this manuscript to be published. MP made substantial contributions to conception and design and critically revised the manuscript. He has given final approval of the version to be published. JM has critically revised the manuscript. He has given final approval of the version to be published. FH contributed to the design and actively participated in data collection, analysis and its interpretation. He was involved in drafting the manuscript and revising it critically.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Patient consent Not required.

  • Ethics approval Institutional review board of the University Medical Centre Utrecht (protocol number 17-326/C).

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.